mRNA-based vaccines

A new eBook is now available entitled ‘Riding the mRNA highway: development, manufacturing, and beyond’, sponsored by Thermo Fisher Scientific. Download the eBook to learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications. Topics covered in the eBook include: Expert views on mRNA […]

Download this eBook to learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications. Topics covered in the eBook include: Expert views on mRNA development and manufacturing Advantages of mRNA processes compared to traditional vaccine manufacturing Best practices for scale up of in vitro […]

For the first time, researchers have developed an mRNA vaccine that is 100% effective against a type of bacteria that is lethal to humans, paving the way for effective vaccination against antibiotic-resistant bacteria. The study, conducted in an animal model, demonstrated that all treated animals were fully protected against the bacteria. According to the researchers, […]

mRNA technology helped us to vaccinate the world against SARS-CoV-2. As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta, PhD, staff scientist in genetic sciences at Thermo Fisher Scientific.  Approximately 7,000 rare and […]

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding.  The Leducq Foundation has announced support for the University of Queensland-led project that could reduce Strep A infections, which cause more than 500,000 deaths a year – with about 70% resulting from rheumatic heart […]

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive Officer and co-founder of BioNTech, […]

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most popular online articles for 2022 […]

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with mRNA-4157/V940, which is being developed by Moderna and Merck (MSD), […]

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial.  In a paper published in Science, the researchers reveal critical new insights into their novel vaccine strategy, which involves a stepwise approach to producing antibodies […]

Stream this free webinar, hosted by DDW and supported by Catalent, Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies. The webinar was presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), […]